Immune cells responsive to IL-10 and TGF-β

Immune cells responsive to IL-10 and TGF-β represent a heterogeneous population of leukocytes, primarily including regulatory T cells (Tregs), M2-polarized macrophages, and myeloid-derived suppressor cells (MDSCs), that mediate immune tolerance and suppress inflammatory responses (Nature Reviews Immunology, 2017). These cells utilize Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β) signaling pathways to maintain homeostatic balance and prevent autoimmunity, but they are often co-opted by tumors to create an immunosuppressive microenvironment that facilitates immune evasion (Nature Reviews Cancer, 2020). Therapeutic strategies targeting these cells involve either enhancing their function to treat autoimmune and inflammatory disorders or inhibiting their activity to restore anti-tumor immunity in oncology (Immunity, 2014). Drugs interacting with this 'target' typically act as agonists or antagonists of the IL-10 and TGF-β receptors or their downstream signaling effectors like STAT3 and SMAD proteins (PubMed, 2021). Monitoring these cell populations often involves assessing specific surface markers and transcription factors such as FoxP3 and CD25 (Journal of Clinical Investigation, 2019). Understanding the interplay between these cytokines and the responsive immune landscape is critical for developing effective immunotherapies (Frontiers in Immunology, 2021).

Other names

IL-10 and TGF-beta responsive immune cellsImmunosuppressive immune cellsRegulatory immune cell populations

Modulation of immunosuppressive signaling pathways via IL-10 receptor agonism or TGF-beta receptor antagonism to alter the recruitment, differentiation, and activity of regulatory immune cells (ClinicalTrials.gov; PubMed, 2022).